RayKnowChina Research Map
Shortlist0

RecruitingStomach cancerPhase 1

Registered title, quoted from ClinicalTrials.gov

A Study of BL-M17D1 in Patients With Locally Advanced or Metastatic HER2 Positive/Lower Expression Gastrointestinal Cancer and Other Solid Tumors

An open trial on stomach cancer, registered on ClinicalTrials.gov. The lead sponsor is not a hospital on this site; 1 hospital on this site is listed as study site.

Status, phase and start date as registered on ClinicalTrials.gov on 8 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.

The study team’s contact details are on the registry record. This site does not pass on enquiries.

Hospitals in mainland China listed for this trial 1

Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.

  1. Study siteSun Yat-sen University Cancer Center中山大学肿瘤防治中心GuangzhouHospital page

The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov

Source: ClinicalTrials.gov record NCT06500052, read on 8 Nov 2026; hospital names matched to this site’s hospital list. How names are matched

Checklist for this trial 8

Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.

Show the checklist (8 points)Hide the checklist
  1. 18 years to 75 years; sex: all

    Registered eligibility fields

  2. The pathologic histology and/or cytology diagnosis of locally advanced or metastatic positive HER2 / low expression of the digestive tract tumor and other solid tumor;

    Inclusion criterion 5

  3. Age: ≥18 years old and ≤75 years old (stage Ia); ≥18 years old (stage Ib);

    Inclusion criterion 3

  4. Toxicity of previous antineoplastic therapy has returned to ≤ grade 1 defined by NCI-CTCAE v5.0;

    Inclusion criterion 9

    For premenopausal women with childbearing potential, a pregnancy test must be performed within 7 days before the initiation of treatment, serum pregnancy must be negative, and must be non-lactating; All the patients (no matter male or female) shall be 6 months after the end of the treatment period and full barrier precautions.

    Inclusion criterion 14

  5. ECOG 0 or 1;

    Inclusion criterion 8

  6. Must have at least one measurable lesion according to RECIST v1.1 definition;

    Inclusion criterion 7

  7. Other malignant tumors diagnosed within 5 years before the first dose;

    Exclusion criterion 5

    HIV antibody positive, active tuberculosis, active hepatitis B virus infection, or active hepatitis C virus infection;

    Exclusion criterion 16

  8. Pregnant or lactating women;

    Exclusion criterion 19

Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: blood tests: counts, liver and kidney function.

Questions to ask the study team

Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT06500052, read on 10 Nov 2026.

Registered criteria

Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.

Inclusion Criteria:

  • Voluntarily sign the informed consent and follow the requirements of the protocol;
  • No gender limit;
  • Age: ≥18 years old and ≤75 years old (stage Ia); ≥18 years old (stage Ib);
  • Expected survival time ≥3 months;
  • The pathologic histology and/or cytology diagnosis of locally advanced or metastatic positive HER2 / low expression of the digestive tract tumor and other solid tumor;
  • Consent to provide archival tumor tissue samples or fresh tissue samples from primary or metastatic lesions within 2 years;
  • Must have at least one measurable lesion according to RECIST v1.1 definition;
  • ECOG 0 or 1;
  • Toxicity of previous antineoplastic therapy has returned to ≤ grade 1 defined by NCI-CTCAE v5.0;
  • No severe cardiac dysfunction, left ventricular ejection fraction ≥50%;
  • Organ function level must meet the requirements;
  • Coagulation function: international normalized ratio ≤1.5, and activated partial thromboplastin time ≤1.5ULN;
  • Urine protein ≤2+ or ≤1000mg/24h;
  • For premenopausal women with childbearing potential, a pregnancy test must be performed within 7 days before the initiation of treatment, serum pregnancy must be negative, and must be non-lactating; All the patients (no matter male or female) shall be 6 months after the end of the treatment period and full barrier precautions.

Exclusion Criteria:

  • Anti-tumor therapy such as chemotherapy or biological therapy has been used within 4 weeks or 5 half-lives before the first dose; Mitomycin and nitrosoureas were administered within 6 weeks before the first dose; Oral drugs such as fluorouracil;
  • History of severe heart disease;
  • QT prolongation, complete left bundle branch block, III degree atrioventricular block, frequent and uncontrollable arrhythmia;
  • Active autoimmune and inflammatory diseases;
  • Other malignant tumors diagnosed within 5 years before the first dose;
  • Hypertension poorly controlled by two antihypertensive drugs;
  • Patients with poor glycemic control before the first dose;
  • Have to hormone treatment of interstitial lung disease, or the current with ILD or suspected suffering from such diseases;
  • Complicated pulmonary diseases leading to clinically severe respiratory function impairment;
  • Patients with massive or symptomatic effusions or poorly controlled effusions;
  • Imaging examination showed that the tumor had invaded or wrapped around the chest, neck, pharynx and other large blood vessels;
  • Screening for unstable thrombotic events requiring therapeutic intervention within the preceding 6 months;
  • Patients with active central nervous system metastases;
  • Patients with a history of allergy to recombinant humanized antibody or human-mouse chimeric antibody or to any of the excipients of BL-M17D1;
  • Prior organ transplantation or allogeneic hematopoietic stem cell transplantation;
  • HIV antibody positive, active tuberculosis, active hepatitis B virus infection, or active hepatitis C virus infection;
  • Active infection requiring systemic therapy with serious infection within 4 weeks before informed consent; There were indications of pulmonary infection or active pulmonary inflammation within 2 weeks before informed consent;
  • Participated in another clinical trial within 4 weeks before the first dose;
  • Pregnant or lactating women;
  • Patients with superior vena cava syndrome should not be rehydrated;
  • A history of severe neurological or psychiatric illness;
  • Severe unhealed wound, ulcer, or fracture within 4 weeks before signing the informed consent;
  • Subjects with clinically significant bleeding or obvious bleeding tendency within 4 weeks before signing the informed consent;
  • History of intestinal obstruction, inflammatory bowel disease, or extensive bowel resection or presence of Crohn's disease, ulcerative colitis, or chronic disease Sexual diarrhea;
  • Patients scheduled for vaccination or receiving live vaccine within 28 days before the first dose;
  • Other conditions for participation in the trial were not considered appropriate by the investigator.

Quoted from ClinicalTrials.gov, NCT06500052, participation criteria. Read on 10 Nov 2026.

Where this information comes from

The registry record

ClinicalTrials.gov (US National Library of Medicine), record NCT06500052, read on 8 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.

Diseases and hospitals

The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions

What is left out

Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.

Suggest a correctionClinicalTrials.gov NCT06500052